Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.
作者信息
Tey Siok-Keen, Lane Steven W
机构信息
Division of Cancer Care Services, Royal Brisbane and Women's Hospital.
Cancer Program, QIMR Berghofer MRI, and.
出版信息
Blood Adv. 2022 Mar 8;6(5):1619-1622. doi: 10.1182/bloodadvances.2021004829.
Abstract
摘要
相似文献
1
Better the cure you know: why patients with AML ≥60 years of age should be offered early allogeneic stem cell transplantation.
Blood Adv. 2022 Mar 8;6(5):1619-1622. doi: 10.1182/bloodadvances.2021004829.
2
Not all patients with AML over 60 years of age should be offered early allogeneic stem cell transplantation.
Blood Adv. 2022 Mar 8;6(5):1623-1627. doi: 10.1182/bloodadvances.2021004799.
3
A case report of the second de novo acute myeloid leukemia (AML) following allogeneic stem cell transplantation in a patient with the first AML.
Korean J Intern Med. 2010 Mar;25(1):110-3. doi: 10.3904/kjim.2010.25.1.110. Epub 2010 Feb 26.
4
Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Biol Blood Marrow Transplant. 2015 Nov;21(11):2008-16. doi: 10.1016/j.bbmt.2015.07.019. Epub 2015 Jul 26.
5
The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study.
Haematologica. 2012 Jan;97(1):21-9. doi: 10.3324/haematol.2011.051714. Epub 2011 Sep 20.
6
Recent Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia.
Biol Blood Marrow Transplant. 2020 Sep;26(9):e215-e221. doi: 10.1016/j.bbmt.2020.06.007. Epub 2020 Jun 16.
7
Outcome of allogeneic hematopoietic stem cell transplantation in adult patients with acute myeloid leukemia harboring trisomy 8.
Ann Hematol. 2017 Mar;96(3):469-478. doi: 10.1007/s00277-016-2909-2. Epub 2017 Jan 6.
8
Impact of allogeneic hematopoietic cell transplantation on the outcome of older patients with acute myeloid leukemia.
Best Pract Res Clin Haematol. 2017 Dec;30(4):320-326. doi: 10.1016/j.beha.2017.09.004. Epub 2017 Sep 22.
9
Effectiveness of allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia.
Best Pract Res Clin Haematol. 2021 Dec;34(4):101320. doi: 10.1016/j.beha.2021.101320. Epub 2021 Oct 22.
10
Treatment of acute myeloid leukemia with hematopoietic stem cell transplantation.
Future Oncol. 2009 May;5(4):559-68. doi: 10.2217/fon.09.20.
引用本文的文献
1
Evolution of Allogeneic Stem Cell Transplantation: Main Focus on AML.
Cells. 2025 Apr 10;14(8):572. doi: 10.3390/cells14080572.
2
Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Transplant Cell Ther. 2025 Mar;31(3):174.e1-174.e12. doi: 10.1016/j.jtct.2024.12.021. Epub 2025 Jan 2.
3
Randomized Phase III SIERRA Trial of I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML.
J Clin Oncol. 2025 Jan 10;43(2):201-213. doi: 10.1200/JCO.23.02018. Epub 2024 Sep 19.
4
Lower intensity therapy with cladribine/low dose cytarabine/venetoclax in older patients with acute myeloid leukemia compares favorably with intensive chemotherapy among patients undergoing allogeneic stem cell transplantation.
Cancer. 2024 Oct 1;130(19):3333-3343. doi: 10.1002/cncr.35388. Epub 2024 May 29.
5
Current knowledge about FLT3 gene mutations, exploring the isoforms, and protein importance in AML.
Mol Biol Rep. 2024 Apr 16;51(1):521. doi: 10.1007/s11033-024-09452-2.
6
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE).
Cancers (Basel). 2023 Apr 24;15(9):2441. doi: 10.3390/cancers15092441.
7
Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.
Cancer Med. 2023 Apr;12(8):9332-9350. doi: 10.1002/cam4.5690. Epub 2023 Feb 17.
本文引用的文献
1
Optimizing Risk Stratification in Acute Myeloid Leukemia: Dynamic Models for a Dynamic Therapeutic Landscape.
J Clin Oncol. 2021 Aug 10;39(23):2535-2538. doi: 10.1200/JCO.21.00067. Epub 2021 May 27.
2
Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center.
Front Oncol. 2021 Mar 11;11:649209. doi: 10.3389/fonc.2021.649209. eCollection 2021.
3
Older adults with newly diagnosed high-risk/secondary AML who achieved remission with CPX-351: phase 3 post hoc analyses.
Blood Adv. 2021 Mar 23;5(6):1719-1728. doi: 10.1182/bloodadvances.2020003510.
4
Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort.
Blood Adv. 2021 Jan 12;5(1):176-184. doi: 10.1182/bloodadvances.2020003159.
5
Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
N Engl J Med. 2020 Dec 24;383(26):2526-2537. doi: 10.1056/NEJMoa2004444.
6
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.
N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971.
7
Allogeneic stem cell transplantation for high-risk acute leukemia and maintenance therapy: no time to waste.
Blood Adv. 2020 Jul 14;4(13):3200-3204. doi: 10.1182/bloodadvances.2019000388.
8
Maintenance therapy for high-risk acute leukemia after allogeneic hematopoietic cell transplantation: wait a minute.
Blood Adv. 2020 Jul 14;4(13):3205-3208. doi: 10.1182/bloodadvances.2019000389.
9
Geriatric assessment in older alloHCT recipients: association of functional and cognitive impairment with outcomes.
Blood Adv. 2020 Jun 23;4(12):2810-2820. doi: 10.1182/bloodadvances.2020001719.
10
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low-intensity chemotherapy in acute myeloid leukaemia.
Br J Haematol. 2021 Mar;192(6):1026-1030. doi: 10.1111/bjh.16722. Epub 2020 May 26.
Zotero 插件